Vygon has acquired Perouse Medical, a French company which designs, manufactures and markets cardiovascular medical devices and long-term vascular access devices. The financial terms of the agreement were not disclosed.
Established in 1984, Perouse Medical generated a turnover of €28.2m (US$31.4m) in 2014. It has a presence in 90 countries and a network of 200 distributors. Fifty-five per cent of Perouse Medical’s turnover stems from its international operations.
With French offices in the Oise region (Ivry-le-Temple) and in the Greater Lyon area of the Rhône-Alpes region (Irigny), the company employs 336 people. Perouse Medical will be the cardiovascular and long-term vascular access specialist within the Vygon group. Thomas Walter, the current deputy director general of Perouse Medical, will be responsible for the general management of the company and will join the Vygon Group executive committee.
This operation is in line with Vygon’s development plan and is primarily intended to reinforce the existing product ranges. With this acquisition, Vygon strengthens its position in the adult long-term vascular access market, which is estimated to be worth €1.1bn (US$1.2bn). A press release states that the synergies between Perouse and Vygon’s various product ranges will allow Vygon to expand its portfolio of available products and strengthen its commercial foothold in France and abroad. The operation also aims to develop expertise on new single-use health product families, with a focus on interventional cardiology and the treatment of cardiovascular diseases. This market is worth €2.1bn (US$2.3bn) and is growing at an annual rate of 12%.
Perouse Medical’s patent portfolio, with 162 patents, will become the property of Vygon.
“With this new acquisition, Vygon consolidates its position in the French and international markets, thereby demonstrating its determination to achieve by 2022 the objectives set out in its growth plan,” said Stéphane Regnault, chairman of Vygon’s board of management.